RecruitingPhase 2NCT05789303

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Studying Multiple myeloma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Chicago
Principal Investigator
Benjamin Derman, MD, PA-C
University of Chicago
Intervention
Belantamab mafodotin(drug)
Enrollment
83 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2028

Study locations (1)

Collaborators

GlaxoSmithKline · Amgen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05789303 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

See all trials for Multiple myeloma →

← Back to all trials